Creative Biolabs specializes in exploring and developing innovative therapeutic antibodies, which can be not only used for the treatments of various cancer, but also for other indications with unmet needs. Thriving to be a reliable and trusted contract research organization (CRO) in pharmaceutical area, we have accumulated extensive experience in the discovery and development of therapeutic antibodies, such as monoclonal antibodies, bispecific antibodies, etc. With support from our senior scientists, whom have more than 10 years of experience, and our state-of-the-art equipment, our integrated CRO services will guide our partners through drug discovery and development, ranging from target selection to IND regulatory approval.
Creative Biolabs is committed to helping our clients at every step of antibody drug discovery and development. With extensive regulatory experience and rich laboratory capacity, Creative Biolabs provides its clients with antibody related integrated platforms, covering antibody discovery, engineering, production, development, in vitrobiologics testing, in vivo animal testing, manufacturing, and relevant regulatory services. Our senior scientists have knowledge from a wide range of disciplines and backgrounds to support our innovative services. We are committed to delivering fully compliant data within the timeline promised.
As a thriving pharmaceutical company, Creative Biolabs focuses on developing and commercializing novel therapeutic antibody programs with the goal to treat cancer. We have proposed a variety of Next-IO™ programs with different promising targets or combined targets. Our focus includes a full spectrum of targets in the immune system, such as T cell, B cell, NK cell, DC and macrophage etc. Guided by our advanced strategies, we are dedicated to making the programs most effective by putting 100 percent effort. Our streamlined management and rich CRO experience allow us to seize every opportunity to collaborate with partners to develop therapeutic candidates. We are confident that our Next-IO™ programs will surely become useful along the way.
We promise that our clients will have full ownership and intellectual property rights of of every therapeutic antibody and protein developed in the project. Every step will be accompanied by our guarantee. We will take care of the potential risks, and you only need to enjoy and lead the process.
Currently, we have a wide range of programs in the discovery phase, including monoclonal antibody and antibody combinations. For commercial partners interested in our Next-IOTM programs, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners and their programs enter the market faster. Creative Biolabs also welcomes your proposals if you are interested in co-developing other programs about immuno-oncology. If you are interested in the collaborations, please don’t hesitate to contact us to know more.
For lab research only, cannot be used for any clinical use.